A61P 33/04
Amoebicides
A61P33/04 (Amoebicides) appears on 233 US grants and 424 published applications in this corpus.
Search patents in A61P- Granted patents
- 233
- Published applications
- 424
- Assignees
- 180
- Inventors
- 608
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 3 |
| 2002 | 4 | 3 |
| 2003 | 4 | 21 |
| 2004 | 1 | 13 |
| 2005 | 4 | 13 |
| 2006 | 3 | 13 |
| 2007 | 6 | 7 |
| 2008 | 4 | 21 |
| 2009 | 11 | 25 |
| 2010 | 14 | 73 |
| 2011 | 18 | 22 |
| 2012 | 17 | 29 |
| 2013 | 25 | 19 |
| 2014 | 21 | 25 |
| 2015 | 11 | 16 |
| 2016 | 10 | 24 |
| 2017 | 11 | 15 |
| 2018 | 10 | 11 |
| 2019 | 5 | 13 |
| 2020 | 19 | 19 |
| 2021 | 4 | 7 |
| 2022 | 7 | 8 |
| 2023 | 5 | 12 |
| 2024 | 3 | 4 |
| 2025 | 4 | 6 |
| 2026 | 2 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anticoccidial composition comprising stilbene-based compound, and use thereof2 Jun 2026US 12,642,776 B2Cj Cheiljedang Corporation
- Anticoccidial composition comprising ginkgo leaves and use thereof12 May 2026US 12,622,941 B2Cj Cheiljedang Corporation
- Formulation containing TLR agonist and methods of use9 Dec 2025US 12,491,243 B2Access To Advanced Health Institute
- Formulation containing TLR agonist and methods of use14 Oct 2025US 12,440,559 B2Access To Advanced Health Institute
- Treatment of Acanthamoeba or Balamuthia trophozoites and/or cysts7 Oct 2025US 12,433,872 B2Georgia State University Research Foundation, Inc.
- Cyclic peptide as inhibitors of free-living amoeba21 May 2026US 2026/0139006 A1Purdue Research Foundation
- Pharmaceutical composition for treating or preventing inflammation caused by acanthamoeba29 Jan 2026US 2026/0027214 A1University of Tsukuba
- Depsipeptide and uses thereof25 Dec 2025US 2025/0388624 A1NovoBiotic Pharmaceuticals, LLC
- Pegylated liposomes and methods of use31 Jul 2025US 2025/0241857 A1Access To Advanced Health Institute
- Formulation containing tlr agonist and methods of use31 Jul 2025US 2025/0242016 A1Access To Advanced Health Institute
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)162US 8,383,796 B2Medarex, Inc. · 2013
- Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents135US 7,601,354 B2ImmunoGen, Inc. · 2009
- Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof135US 7,767,429 B2Halozyme, Inc. · 2010
- Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates129US 8,088,387 B2ImmunoGen, Inc. · 2012